H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo

Yanting Yang, Daokun Guan, Lei Lei, Jing Lu, Jia Qi Liu, Gangqiang Yang, Chunhong Yan, Rong Zhai, Jingwei Tian, Yi Bi, Fenghua Fu, Hongbo Wang

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment, in which the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α-hederagenin derivative, designated H6, was designed, synthesized and evaluated for its ability to reverse MDR. Our results showed that H6 could sensitize KBV and MCF7/T cells to paclitaxel and vincristine. Meanwhile, H6 could increase both rhodamine 123 and paclitaxel accumulation in MDR cells without affecting the expression of P-gp. Interestingly, siRNA knockdown of MDR1 further sensitized the cytotoxic activity of paclitaxel when co-administrated with H6. In addition, H6 could directly stimulate P-gp ATPase activity in vitro. Importantly, H6 enhanced the efficacy of paclitaxel against KBV cancer cell-derived xenograft tumors in nude mice. Finally, H6 showed high binding affinity with P-gp with a high docking score. Overall, we show H6 is a novel and potent MDR reversal agent, which has the potential to be administered in combination with conventional anticancer drugs.

Original languageEnglish (US)
Pages (from-to)98-105
Number of pages8
JournalToxicology and Applied Pharmacology
Volume341
DOIs
StatePublished - Feb 15 2018

Fingerprint

Multiple Drug Resistance
P-Glycoprotein
Paclitaxel
Derivatives
Rhodamine 123
Neoplasms
Oncology
T-cells
MCF-7 Cells
Vincristine
Heterografts
Nude Mice
Small Interfering RNA
Adenosine Triphosphatases
Tumors
Cells
T-Lymphocytes
In Vitro Techniques
hederagenin
Pharmaceutical Preparations

Keywords

  • H6
  • Molecular docking
  • Multidrug resistance
  • P-glycoprotein
  • α-Hederagenin

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Cite this

H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. / Yang, Yanting; Guan, Daokun; Lei, Lei; Lu, Jing; Liu, Jia Qi; Yang, Gangqiang; Yan, Chunhong; Zhai, Rong; Tian, Jingwei; Bi, Yi; Fu, Fenghua; Wang, Hongbo.

In: Toxicology and Applied Pharmacology, Vol. 341, 15.02.2018, p. 98-105.

Research output: Contribution to journalArticle

Yang, Y, Guan, D, Lei, L, Lu, J, Liu, JQ, Yang, G, Yan, C, Zhai, R, Tian, J, Bi, Y, Fu, F & Wang, H 2018, 'H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo', Toxicology and Applied Pharmacology, vol. 341, pp. 98-105. https://doi.org/10.1016/j.taap.2018.01.015
Yang, Yanting ; Guan, Daokun ; Lei, Lei ; Lu, Jing ; Liu, Jia Qi ; Yang, Gangqiang ; Yan, Chunhong ; Zhai, Rong ; Tian, Jingwei ; Bi, Yi ; Fu, Fenghua ; Wang, Hongbo. / H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo. In: Toxicology and Applied Pharmacology. 2018 ; Vol. 341. pp. 98-105.
@article{6170dcbc2dbb4169bf30f5ce7646bb17,
title = "H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo",
abstract = "Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment, in which the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α-hederagenin derivative, designated H6, was designed, synthesized and evaluated for its ability to reverse MDR. Our results showed that H6 could sensitize KBV and MCF7/T cells to paclitaxel and vincristine. Meanwhile, H6 could increase both rhodamine 123 and paclitaxel accumulation in MDR cells without affecting the expression of P-gp. Interestingly, siRNA knockdown of MDR1 further sensitized the cytotoxic activity of paclitaxel when co-administrated with H6. In addition, H6 could directly stimulate P-gp ATPase activity in vitro. Importantly, H6 enhanced the efficacy of paclitaxel against KBV cancer cell-derived xenograft tumors in nude mice. Finally, H6 showed high binding affinity with P-gp with a high docking score. Overall, we show H6 is a novel and potent MDR reversal agent, which has the potential to be administered in combination with conventional anticancer drugs.",
keywords = "H6, Molecular docking, Multidrug resistance, P-glycoprotein, α-Hederagenin",
author = "Yanting Yang and Daokun Guan and Lei Lei and Jing Lu and Liu, {Jia Qi} and Gangqiang Yang and Chunhong Yan and Rong Zhai and Jingwei Tian and Yi Bi and Fenghua Fu and Hongbo Wang",
year = "2018",
month = "2",
day = "15",
doi = "10.1016/j.taap.2018.01.015",
language = "English (US)",
volume = "341",
pages = "98--105",
journal = "Toxicology and Applied Pharmacology",
issn = "0041-008X",
publisher = "Academic Press Inc.",

}

TY - JOUR

T1 - H6, a novel hederagenin derivative, reverses multidrug resistance in vitro and in vivo

AU - Yang, Yanting

AU - Guan, Daokun

AU - Lei, Lei

AU - Lu, Jing

AU - Liu, Jia Qi

AU - Yang, Gangqiang

AU - Yan, Chunhong

AU - Zhai, Rong

AU - Tian, Jingwei

AU - Bi, Yi

AU - Fu, Fenghua

AU - Wang, Hongbo

PY - 2018/2/15

Y1 - 2018/2/15

N2 - Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment, in which the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α-hederagenin derivative, designated H6, was designed, synthesized and evaluated for its ability to reverse MDR. Our results showed that H6 could sensitize KBV and MCF7/T cells to paclitaxel and vincristine. Meanwhile, H6 could increase both rhodamine 123 and paclitaxel accumulation in MDR cells without affecting the expression of P-gp. Interestingly, siRNA knockdown of MDR1 further sensitized the cytotoxic activity of paclitaxel when co-administrated with H6. In addition, H6 could directly stimulate P-gp ATPase activity in vitro. Importantly, H6 enhanced the efficacy of paclitaxel against KBV cancer cell-derived xenograft tumors in nude mice. Finally, H6 showed high binding affinity with P-gp with a high docking score. Overall, we show H6 is a novel and potent MDR reversal agent, which has the potential to be administered in combination with conventional anticancer drugs.

AB - Multidrug resistance (MDR) is a serious obstacle encountered in cancer treatment, in which the overexpression of P-glycoprotein (P-gp) plays an important role. Here, a novel α-hederagenin derivative, designated H6, was designed, synthesized and evaluated for its ability to reverse MDR. Our results showed that H6 could sensitize KBV and MCF7/T cells to paclitaxel and vincristine. Meanwhile, H6 could increase both rhodamine 123 and paclitaxel accumulation in MDR cells without affecting the expression of P-gp. Interestingly, siRNA knockdown of MDR1 further sensitized the cytotoxic activity of paclitaxel when co-administrated with H6. In addition, H6 could directly stimulate P-gp ATPase activity in vitro. Importantly, H6 enhanced the efficacy of paclitaxel against KBV cancer cell-derived xenograft tumors in nude mice. Finally, H6 showed high binding affinity with P-gp with a high docking score. Overall, we show H6 is a novel and potent MDR reversal agent, which has the potential to be administered in combination with conventional anticancer drugs.

KW - H6

KW - Molecular docking

KW - Multidrug resistance

KW - P-glycoprotein

KW - α-Hederagenin

UR - http://www.scopus.com/inward/record.url?scp=85041408451&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041408451&partnerID=8YFLogxK

U2 - 10.1016/j.taap.2018.01.015

DO - 10.1016/j.taap.2018.01.015

M3 - Article

C2 - 29408042

AN - SCOPUS:85041408451

VL - 341

SP - 98

EP - 105

JO - Toxicology and Applied Pharmacology

JF - Toxicology and Applied Pharmacology

SN - 0041-008X

ER -